Cargando…

CES1‐Triggered Liver‐Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration

The broad application of clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome editing tools is hindered by challenges in the efficient delivery of its two components into specific cells and intracytoplasmic release. Herein, a novel copolymer for delivery of Cas9‐mRNA/ single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yunfei, Li, Yun, Wang, Fan, Gan, Xuelan, Zheng, Tianye, Chen, Mengyue, Wei, Li, Chen, Jun, Yu, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323666/ https://www.ncbi.nlm.nih.gov/pubmed/37083231 http://dx.doi.org/10.1002/advs.202300502

Ejemplares similares

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
por: Emmer, Brian T, et al.
Publicado: (2018)

In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system
por: Li, Qian, et al.
Publicado: (2021)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
por: Kim, Young Uk, et al.
Publicado: (2019)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4
por: Wang, Bingxiang, et al.
Publicado: (2021)

Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression
por: Zhao, Xue-Shan, et al.
Publicado: (2017)

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
por: Cai, Hua, et al.
Publicado: (2023)

Nanodevices for the Efficient Codelivery of CRISPR-Cas9 Editing Machinery and an Entrapped Cargo: A Proposal for Dual Anti-Inflammatory Therapy
por: García-Fernández, Alba, et al.
Publicado: (2022)

In Vitro CRISPR/Cas9 Transfection and Gene-Editing Mediated by Multivalent Cationic Liposome–DNA Complexes
por: Sousa, Diana A., et al.
Publicado: (2022)

Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia
por: Wu, Chenglin, et al.
Publicado: (2019)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
por: Basiak, Marcin, et al.
Publicado: (2022)

CRISPR-Cas9 DNA Base-Editing and Prime-Editing
por: Kantor, Ariel, et al.
Publicado: (2020)

CRISPR/Cas9 or prime editing? – It depends on…
por: Schenke, Dirk
Publicado: (2020)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

A cationic lipid mediated CRISPR/Cas9 technique for the production of stable genome edited citrus plants
por: Mahmoud, Lamiaa M., et al.
Publicado: (2022)

Cationic Copolymerization of Isobutylene with 4-Vinylbenzenecyclobutylene: Characteristics and Mechanisms
por: Chen, Zhifei, et al.
Publicado: (2020)

Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing
por: Fang, Tianxu, et al.
Publicado: (2022)

Recent Advances in Genome Editing Using CRISPR/Cas9
por: Ding, Yuduan, et al.
Publicado: (2016)

CRISPR-Cas9: from Genome Editing to Cancer Research
por: Chen, Si, et al.
Publicado: (2016)

Editing of Genomic TNFSF9 by CRISPR-Cas9 Can Be Followed by Re-Editing of Its Transcript
por: Lee, Hyeon-Woo
Publicado: (2018)

Expanding CRISPR/Cas9 Genome Editing Capacity in Zebrafish Using SaCas9
por: Feng, Yan, et al.
Publicado: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
por: Zhang, Song, et al.
Publicado: (2021)

Easy quantification of template-directed CRISPR/Cas9 editing
por: Brinkman, Eva K, et al.
Publicado: (2018)

Inducible in vivo genome editing with CRISPR/Cas9
por: Dow, Lukas E, et al.
Publicado: (2015)

Efficient Mitochondrial Genome Editing by CRISPR/Cas9
por: Jo, Areum, et al.
Publicado: (2015)

CRISPR/Cas9: Transcending the Reality of Genome Editing
por: Chira, Sergiu, et al.
Publicado: (2017)

Genome Editing in Cotton with the CRISPR/Cas9 System
por: Gao, Wei, et al.
Publicado: (2017)

CRISPR/Cas9 Editing for Gaucher Disease Modelling
por: Pavan, Eleonora, et al.
Publicado: (2020)

Spatiotemporal control of CRISPR/Cas9 gene editing
por: Zhuo, Chenya, et al.
Publicado: (2021)

Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing
por: Duan, Li, et al.
Publicado: (2021)

CRISPR–Cas9 Based Bacteriophage Genome Editing
por: Zhang, Xueli, et al.
Publicado: (2022)

CRISPR/Cas9 genome editing for neurodegenerative diseases
por: Nouri Nojadeh, Jafar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ffhedgikcj523knru13hml20sm